Highlighting survival with yttrium-90 radioembolization therapy in unresectable hepatocellular carcinoma
Nabrinsky E, James E. Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma. Cureus. 2020 May 16;12(5):e8163. doi: 10.7759/cureus.8163. PMID: 32550079; PMCID: PMC7296880
Unresectable hepatocellular carcinoma has several different therapeutic options, including targeted agents as well as locoregional therapy. Yttrium-90 (Y90) radioembolization therapy is an established treatment for unresectable disease and has been compared to other locoregional options as well as different targeted therapies. Newer case series are also reporting a potential benefit to the addition of immunotherapy to Y90 radioembolization. Here we report a case of prolonged survival in a patient whose treatment course included Y90 radioembolization along with sorafenib and nivolumab.